VanEck Pharmaceutical ETF
$110.36−1.52 (−1.36%)
- Expense ratio
- 0.36%
- Fund size
- $1.0B
- 1Y return
- +29.1%
- Yield · Last 12 months
- 1.94%
- Holdings
- 26
- Volume · 30D
- 0.3M sh
- NAV per share
- $111.66
- 52W range
The ETF.net PPH Grade
Score 73 of 100 sits in the A band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.AScore 79Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.AScore 80Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 56Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.AScore 93Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.CScore 40Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 73Category rank
Our read on PPH
AAbout two dozen US-listed drugmakers in one ticker, tracking the MVIS US Listed Pharmaceutical 25 Index since 2011. VanEck charges well under the pharma-fund median to run it.
The fund seeks to track, before fees and expenses, the performance of the MVIS US Listed Pharmaceutical 25 Index, which covers companies involved in pharmaceutical research and development, production, marketing, and sales.
Why people hold it
- Costs 0.36% a year against a 0.57% median for pharma ETFs, undercutting peers like PJP and FTXH.
- Focused by design: the index tracks US-listed pharmaceutical companies (research, production, marketing, sales) rather than the whole health care aisle.vaneck.com
- Trading since 2011, one of the veterans of the pharma shelf, and it sits in the top quartile of its peer group on our review.
- Pays out quarterly, and it is a moderately traded fund, so getting in and out is usually straightforward.
Worth knowing
- Around 26 holdings. One company's trial result or patent cliff carries real weight in a basket this tight.
- Single-sector health care exposure: drug pricing politics and regulation land on the whole basket at once, with nothing else to cushion it.
- The fee edge over the category is real, but XPH sits at 0.35%, so cost alone is not what separates these two.
PPH Holdings
- Stocks
- 26
- 72%
- LLY
Sectors
- Health Care100.0%
Geography
- United States62.94%
- United Kingdom10.92%
- Switzerland9.30%
- Denmark4.80%
- France4.01%
- Israel3.45%
- Japan3.29%
- Ireland1.17%
- 0.12%
Developed 91% · Emerging 9%
PPH Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
PPH$12,908
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PPH |
|---|---|
| Year to date | +9.9% |
| 1 month | −4.1% |
| 3 months | +8.8% |
| 1 year | +29.1% |
| 3 years | +13.8% |
| 5 years | +11.1% |
| 10 years | +8.6% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PPH |
|---|---|---|
| 2026 YTD | +9.9% | |
| 2025 | +22.0% | |
| 2024 | +8.1% | |
| 2023 | +7.0% | |
| 2022 | +2.6% | |
| 2021 | +17.8% | |
| 2020 | +5.5% |
PPH in the news
PPH Dividends
- 1.94%
- $2.17
- $0.62 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Jul 1, 2026 | Jul 7, 2026 | $0.62 |
| Apr 1, 2026 | Apr 7, 2026 | $0.84 |
| Dec 29, 2025 | Dec 31, 2025 | $0.31 |
| Oct 1, 2025 | Oct 6, 2025 | $0.39 |
| Jul 1, 2025 | Jul 7, 2025 | $0.61 |
| Apr 1, 2025 | Apr 4, 2025 | $0.52 |
| Dec 27, 2024 | Dec 30, 2024 | $0.41 |
| Oct 1, 2024 | Oct 4, 2024 | $0.41 |
| Jul 1, 2024 | Jul 5, 2024 | $0.36 |
| Apr 1, 2024 | Apr 5, 2024 | $0.53 |
| Dec 27, 2023 | Dec 29, 2023 | $0.31 |
| Oct 2, 2023 | Oct 6, 2023 | $0.34 |
PPH Risk
- 13.8%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.67
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −20.3%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.41
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PPH Cost
0.36%
PPH0.36%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
2 of the 9 Pharma & Therapeutics funds charge less.